Vivani Medical Inc Dossier
Qualitative Analysis
Business overview
Vivani Medical, Inc. (Nasdaq: VANI) is a clinical-stage biopharmaceutical company focused on developing miniaturized, ultra-long-acting subdermal drug implants. The company utilizes its proprietary NanoPortal™ technology platform, which is designed to provide near-constant, reversible, and controlled delivery of a wide range of therapeutic molecules to treat chronic diseases. Vivani's primary focus is on chronic weight management and type 2 diabetes, addressing critical patient challenges such as medication non-adherence, tolerability, and administration frequency. The company operates through two main segments: its core Biopharm Division (drug implants) and its Neurostimulation Division (under its subsidiary Cortigent, Inc.).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing and accelerating the clinical development of NPM-139, a miniature, ultra long-acting subdermal semaglutide implant utilizing proprietary NanoPortal technology for chronic weight management.
Expected impact: Aims to address medication non-adherence and tolerability challenges in the GLP-1 obesity market by providing a once- or twice-yearly dosing alternative.
Exploring strategic alternatives to separate the wholly owned neurostimulation subsidiary, Cortigent, Inc., into an independent, publicly traded company.
Expected impact: Allows Vivani to focus exclusively on its core biopharmaceutical pipeline while enabling shareholders to directly participate in Cortigent's neurostimulation and brain-computer interface technologies.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Leverages Vivani's NanoPortal platform to develop OKV-119, an ultra long-acting GLP-1 (exenatide) implant for feline and canine metabolic conditions (obesity and diabetes).
Terms: Minimizes costs and risks for Vivani while providing upside potential through future milestone payments and royalties.